TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo. [electronic resource]
Producer: 20170302Description: 36456-71 p. digitalISSN:- 1949-2553
- Aniline Compounds -- administration & dosage
- Animals
- Antineoplastic Combined Chemotherapy Protocols -- pharmacology
- Apoptosis -- drug effects
- Brain Neoplasms -- drug therapy
- Drug Synergism
- Female
- Glioblastoma -- drug therapy
- Heterocyclic Compounds, 4 or More Rings -- administration & dosage
- Humans
- Imidazoles
- MAP Kinase Signaling System -- drug effects
- Male
- Mice
- Mice, SCID
- Myeloid Cell Leukemia Sequence 1 Protein -- antagonists & inhibitors
- Proto-Oncogene Proteins c-bcl-2 -- antagonists & inhibitors
- Pyridines
- Pyrimidines
- Random Allocation
- Sulfonamides -- administration & dosage
- Xenograft Model Antitumor Assays
- bcl-X Protein -- antagonists & inhibitors
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.